LP
LXRX icon

LMR Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

LMR Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.6K Buy
41,091
+17,786
+76% +$34.6K ﹤0.01% 1373
2026
Q1 		$36.4K Buy
+23,305
New +$33.9K ﹤0.01% 1325

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LMR Partners's LXRX Position: Q2 2026 in Review

LMR Partners increased its Lexicon Pharmaceuticals (LXRX) stake by 76% in Q2 2026, buying an estimated $34.6K and bringing the position to 41,091 shares worth $98.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

LMR Partners first reported a position in LXRX in Q1 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • LMR Partners held 41,091 shares of Lexicon Pharmaceuticals worth $98.6K as of Q2 2026.
  • LMR Partners bought 17,786 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $34.6K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1373 holding.
  • LMR Partners first reported a position in Lexicon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.